Media Articles Related to Istodax (Romidepsin)
Researchers Discover Master Regulator That Drives Majority Of Lymphoma
Source: Health News from Medical News Today [2013.05.17]
New Findings Show Inhibiting Powerful Protein with New Agents May Supply Broad Benefit for Lymphoma Patients A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell Medical College, now report that these agents may, in fact, help a much broader cross section of lymphoma patients...
Inhibiting Powerful Protein With New Agents May Supply Broad Benefit For Lymphoma Patients
Source: Genetics News From Medical News Today [2013.05.15]
A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell Medical College, now report that these agents may, in fact, help a much broader cross section of lymphoma patients...
The Search For Therapeutic Synergy In Primary Effusion Lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2013.05.03]
Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because current treatment options are not effective, there is a great need for new PEL therapies...
New Strategy Helps Young Lymphoma Patients Avoid Radiation Treatment
Source: MedicineNet Leukemia Specialty [2013.04.11]
Title: New Strategy Helps Young Lymphoma Patients Avoid Radiation Treatment
Category: Health News
Created: 4/10/2013 6:35:00 PM
Last Editorial Review: 4/11/2013 12:00:00 AM
Melanoma Odds Doubled for Transplant, Lymphoma Patients: Study
Source: MedicineNet Hodgkins Disease Specialty [2012.10.11]
Title: Melanoma Odds Doubled for Transplant, Lymphoma Patients: Study
Category: Health News
Created: 10/10/2012 2:05:00 PM
Last Editorial Review: 10/11/2012 12:00:00 AM
Published Studies Related to Istodax (Romidepsin)
Romidepsin: a novel histone deacetylase inhibitor for cancer. [2011.08]
Introduction: Romidepsin is a novel histone deacetylase (HDAC) inhibitor, with a recent approval for treatment of cutaneous T-cell lymphoma (CTCL).Future directions include expanded indications in T-cell lymphomas as well as novel combinations with other HDAC inhibitors and other therapeutic agents.
Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. [2011.08]
Romidepsin (Istodax), a selective inhibitor of histone deacetylases (HDACs), was approved for the treatment of cutaneous T-cell lymphoma in November 2009 by the US Food and Drug Administration. This unique natural product was discovered from cultures of Chromobacterium violaceum, a Gram-negative bacterium isolated from a Japanese soil sample...
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. [2011.06.02]
Romidepsin (depsipeptide or FK228) is a histone deacetylase inhibitor, one of a new class of agents active in T-cell lymphoma. A phase 2 trial was conducted in cutaneous (CTCL) and peripheral (PTCL) T-cell lymphoma... The histone deacetylase inhibitor romidepsin has single agent clinical activity associated with durable responses in patients with relapsed PTCL.
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. [2011.05]
Romidepsin, a potent histone deacetylase inhibitor, has shown activity in preclinical glioma models. The primary objectives of this trial were to determine the pharmacokinetics of romidepsin in patients with recurrent glioma on enzyme-inducing antiepileptic drugs (EIAEDs) and to evaluate the antitumor efficacy of romidepsin in patients with recurrent glioblastoma who were not receiving EIAEDs...
Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin. [2011.04]
OBJECTIVE: To investigate whether the histone deacetylase (HDAC) inhibitor romidepsin down-regulates VEGF (vascular endothelial growth factor) gene expression and abrogates VEGF protein secretion in human epithelial endometriotic cells. DESIGN: In vitro study with human immortalized epithelial endometriotic cells.
Clinical Trials Related to Istodax (Romidepsin)
A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas [Recruiting]
This study is an open label, multicenter study with two phases:
- A dose escalation phase of Romidepsin administered IV at day 1 and 8 or at day 1
without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and
prednisone (CHOP)administered every 3 weeks for 8 cycles in patients with T-cell
- An expansion phase in order to assess the safety and the efficacy of the association of
the recommended dose of Romidepsin associated with CHOP in a population of patients
with T-cell lymphoma.
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction [Recruiting]
This research is being done to study the safety of the anti-cancer drug romidepsin at
different dose levels in patients with cancer who have different degrees of abnormal liver
function. Romidepsin works by entering cancer cells and blocking the activity of proteins
that are important for the cancer's growth and survival
Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma [Recruiting]
The goal of this clinical research study is find the highest tolerable dose of romidepsin
that can be given in combination with ifosfamide, carboplatin, etoposide (ICE) to patients
with Peripheral T-Cell Lymphoma (PTCL). The safety of this drug combination will also be
Romidepsin is designed to stop the growth of cancer cells and block new blood vessels from
forming around the cancer cells. This may cause the cancer cells to die.
Ifosfamide and etoposide are designed to slow or stop the growth of cancer cells.
Carboplatin is designed to interfere with the growth of cancer cells by stopping cell
division, which may cause the cells to die.
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma [Recruiting]
This randomized phase I trial studies the side effects and the best dose of carfilzomib when
given together with or without romidepsin in treating patients with stage IA-IVB cutaneous
T-cell lymphoma. Carfilzomib and romidepsin may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. It is not yet known whether giving carfilzomib
alone is more effective than when given together with romidepsin.
Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma [Recruiting]
- Cutaneous T-cell lymphoma (CTCL) is a rare, slow-growing form of skin cancer. The
cancer cells are found in red, scaly patches that may sometimes itch.
- Early-stage CTCL is usually treated with topical therapies, which may lose
effectiveness over time and have adverse effects, such as risk of secondary skin
cancers and difficulty of use.
- Romidepsin is an experimental drug that, given through a vein, has improved CTCL in
some patients with later stages of the disease.
- A topical ointment form of romidepsin may be helpful in treating early-stage CTCL.
- To determine the highest tolerated dose of topical romidepsin that can be given to
patients with early-stage CTCL.
- To evaluate the effectiveness of topical romidepsin in patients with early-stage CTCL.
- To determine how the body handles topical romidepsin.
- Patients 18 of age and older with early-stage CTCL.
- Study Part 1: Successive groups of 3 patients are treated with increasingly higher
concentrations of topical romidepsin until the highest tolerated dose is found.
- Study Part II: The highest tolerated dose, as determined in Part I, is applied to
larger areas of skin in another group of patients.
- All study participants apply the study medicine to their skin three times a day for 4
- During treatment, participants are monitored at weeks 2 and 4 with a history and
physical examination, blood tests, electrocardiogram, skin biopsies and photographs of
- After stopping treatment, participants return to the clinic at weeks 6 and 8 for blood
tests and to see how the study medication is affecting the body.
Reports of Suspected Istodax (Romidepsin) Side Effects
Decreased Appetite (6),
Pulmonary Oedema (5),
Infusion Site Extravasation (4),
Peripheral Sensory Neuropathy (4),
General Physical Health Deterioration (4),
Febrile Neutropenia (4), more >>